Unichem Laboratories Ltd. (BSE: 506690) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹3,593 Cr, it ranks #976 by market cap among the 6,137 Indian listed companies on FinBizNet, and #32 of 86 in Medicinal Chemicals and Botanical Products. At ₹472.95 (as of 25 Oct 2026), the share price is 31.2% below its 52-week high of ₹687.20 and 70.0% above its 52-week low of ₹278.20. The share price is up 0.8% over one year and down 12.0% over three months.
| Current Price | ₹472.95 |
|---|---|
| Market Cap | ₹3,593 Cr |
| BSE Code | 506690 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 14.1 |
| Return on Equity | 9.78% |
| Return on Assets | 1.09% |
| 52-Week Range | ₹278.20 – ₹687.20 |
| 1-Year Price Change | +0.8% |
| 3-Month Price Change | -12.0% |
| Beta (1Y) | 0.26 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.unichemlabs.com |
| Revenue | ₹633 Cr |
|---|---|
| Net Profit | ₹41 Cr |
| Net Margin | 6.6% |
| EPS (Basic) | ₹6.61 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. It serves patients, distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.
1. Pharmaceuticals-This segment manufactures and sells pharmaceutical products.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Unichem Laboratories Ltd. | ₹3,593 Cr | 14.1 | 9.78% | ₹633 Cr | +0.8% |
Listed by market capitalisation. Ratios are shown for context only.
Unichem Laboratories Ltd. is trading at ₹472.95, with a market capitalisation of ₹3,593 Cr.
Unichem Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Unichem Laboratories Ltd. has a P/E of 14.1 and a return on equity of 9.78%.
Unichem Laboratories Ltd. is listed on the BSE under the scrip code 506690.
Unichem Laboratories Ltd.'s share price is up 0.8% over one year and down 12.0% over three months. Its 52-week range is ₹278.20 to ₹687.20.
In Q1 FY27, Unichem Laboratories Ltd. reported revenue of ₹633 Cr and net profit of ₹41 Cr, with basic EPS of ₹6.61 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.